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These experiments were designed to assess the 
ability of the n e w nonpeptide angiotensin II antag­
onist DuP 753 to inhibit the binding and, particu­
larly, to antagonize the cellular response to angio­
tensin II in human platelets and primary cultures 
of rat aortic smooth muscle cells (SMC). The binding 
of 1 2 5 I -angiotens in II was competitively inhibited 
by DuP 753 with a 50% binding inhibit ion (IC^) of 
5 to 6 X 10" 8 m o l / L in platelets and 1 X 10" 8 m o l / L 
in vascular SMC as compared to an I C ^ of 5 to 7.5 X 
10~ 9 m o l / L with nonlabeled angiotensin II. In vas­
cular SMC, DuP 753 completely abolished the ef­
fects of angiotensin II on 4 5 C a C l 2 efflux and 4 5 C a C l 2 
uptake. Moreover, in these latter cells, DuP 753 
prevented the angiotensin II but not the vasopressin 
induced increase in cytosolic calcium. These results 
demonstrate that DuP 753 competes wi th angioten­
sin II b inding to its receptor in both animal and 
human cells and selectively blocks the cellular re­
sponse to angiotensin II. A m J Hypertens 1991;4:438-
443 
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Blockade of the renin-angiotensin system (RAS) has become in recent years a very effective ap­proach for the treatment of hypertension and congestive heart f a i l u r e . 1 - 4 Today, the cascade 
of the RAS leading to the generation of angiotensin II 
(Ang II) and finally to the activation of the angiotensin II 
receptor can be interrupted at different sites either by 
inhibition of renin or angiotensin converting enzyme 
(ACE) or by direct competition with the binding of an­
giotensin II to its r e c e p t o r . 5 - 7 
Historically, saralasin, a peptide analog of Ang II, was 
the first potent and specific receptor antagonist to be 
used to block the activity of the RAS. 7 This drug allowed 
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the crucial role of the RAS in the development and main­
tenance of hypertension in animal models 8 - 9 and in 
h u m a n forms of hypertension to be d e m o n s t r a t e d . 1 0 - 1 2 
The clinical use of this receptor antagonist, however, 
has been limited by its lack of oral bioavailability, its 
short duration of action, and by its inherent agonistic 
a c t i v i t y . 1 0 - 1 2 
Recently, several nonpept ide imidazole Ang II recep­
tor antagonists have been p r o d u c e d . 1 3 1 4 These com­
pounds exhibit a high affinity for Ang II binding sites in 
r a t s . 1 5 Moreover, they have been shown to decrease 
blood pressure in animal models of hypertension partic­
ularly in those associated with an increased activity of 
the R A S . 1 5 1 6 DuP 753 is one of these n e w orally active 
Ang II receptor antagonists that effectively inhibit Ang 
II binding in v i t r o 1 5 1 7 and exert functional Ang II antago­
nism in rabbit aor ta . 1 7 Oral administration of D u P 753 to 
renal hypertensive rats causes a dose-dependent de­
crease in blood p r e s s u r e . 1 5 - 1 8 In heal thy h u m a n volun­
teers, DuP 753 given orally abolishes the blood pressure 
response to exogenous Ang I I . 1 9 
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The present experiments were designed to study the 
ability of D u P 753 to inhibit the binding of Ang II in 
h u m a n platelets much as it does in rat vascular smooth 
muscle cells. In addition, the capacity of DuP 753 to 
antagonize the cellular calcium response to Ang II was 
evaluated in primary cultures of rat aortic smooth mus ­
cle cells. 
M E T H O D S 
Bind ing S tud ies Angiotensin II binding was per­
formed both on freshly isolated h u m a n platelets and 
primary cultures of rat aortic smooth muscle cells 
(SMC). 
Angiotensin II Binding in Human Platelets Blood was 
drawn from the forearm veins of heal thy volunteers and 
anticoagulated with sodium citrate. Platelets were then 
isolated as described by Le Quan Sang and Devynck . 2 0 
Platelet-rich plasma was washed twice at room tempera­
ture in Medium 199 containing 5 m m o l / L EDTA, 0.2% 
bovine serum albumin (BSA), 10 m m o l / L HEPES and 
1 m g / m L bacitracin (pH 7.4, 22 °C) (assay buffer). The 
platelets were counted automatically and the volume 
was adjusted to yield a concentration of 10 6 cells///L. 
Binding studies were performed as described by Mann 
et a l . 2 1 In brief, platelets were incubated for 3 h with 
0.1 n m o l / L 1 2 5 I -angiotensin II in a final volume of 
100 ßL at 37°C in a shaking water bath. Incubations 
were s topped by dilution with assay buffer at 4°C and 
centrifugation at 10000 g for 5 min. The supernatant 
was discarded and the platelets washed twice in me­
dium 199 at 4°C. Radioactivity was counted in a y-
counter. Nonspecific binding was assessed by adding 
unlabeled angiotensin II at 1 0 " 6 mo l /L . Displacement 
of specifically bound 1 2 5 I -angiotensin II was performed 
with increasing concentrations of Ang II, DuP 753 (Du 
Pont de Nemours , Wilmington, DE) and a nonrelevant 
peptide (morphine modulat ing peptide, MMP). 
Angiotensin II Binding in Vascular Smooth Muscle Cells 
Primary cultures of rat aortic smooth muscle (6th to 7th 
passage) cultured in Dulbecco's Modified Eagle Me­
dium (DMEM) with 15% fetal calf serum were used for 
these studies. Binding was performed 3 to 5 days after 
plating the cells on 3.5 cm dishes. At confluence, the 
cells were washed with the assay buffer (Medium 199 
containing 0.2% BSA, 1 m g / m L bacitracin, and 
10 m m o l / L HEPES). They were then incubated for 1 h 
at 37°C with 0.01 n m o l / L 1 2 5 I -angiotensin II. The ex­
periments were terminated by aspirating the superna­
tant and washing the cells three times with the binding 
buffer. The cells were removed from the plates with a 
lysis buffer containing 0 . 1 % sodium dodecyl sulphate 
(SDS), 2 % N a 2 C 0 3 and 0.1 Ν N a O H and scraping with 
a "rubber policeman." Radioactivity was counted in a 
y-counter. Displacement curves were performed with 
increasing concentrations of unlabeled angiotensin II, 
DuP 753, or saralasin. 
Ca lc ium Studies i n Vascular Smoo th Musc le Cel ls 
Primary cultures of rat aortic SMC (7th to 10th passage) 
grown to confluence in DMEM were used to study the 
ability of DuP 753 to interfere with the cellular response 
to Ang II. 
45Ca2+ Efflux The culture med ium was removed by aspi­
ration and the cells washed twice with a physiologic 
saline solution (PSS) and loaded with 5 //Ci of 4 5 C a C l 2 in 
1 mL PSS at 37°C for 3 h. After loading, the cultures 
were rapidly rinsed five times and another 1 mL of fresh 
PSS was added. The supernatant was removed and re­
placed with 1 mL PSS every 30 sec for 6 min. The direct 
effects of Ang II or DuP 753 were evaluated by adding 
the peptide or the drug at 3 min. In some experiments, 
pretreatment with DuP 753 was done by adding various 
concentrations of the antagonist in the PSS buffer con­
tinuously from time 0. The amount of 4 5 C a 2 + lost from 
the cells in 12 consecutive 30 sec intervals and the 
amount remaining inside the cells at the end of the 
6 min experiment was measured by liquid scintillation 
counting. The results are expressed as the percentage of 
the total 4 5 C a 2 + activity released in the supernatant dur­
ing a 30 sec time interval. 
45Ca2+ Uptake The culture med ium was removed and 
the cells washed several times with fresh PSS. The cells 
were allowed to equilibrate for 3 h in this n e w buffer. 
They were then incubated for 5 min with 2 //Ci 4 5 C a C l 2 
in the presence or absence of any effector in 1 mL PSS. 
To terminate uptake, extracellular 4 5 C a C l 2 was removed 
by washing the cells rapidly five times with cold PSS 
containing 2 m m o l / L EDTA. The cells were lysed with 
the lysis buffer described above and the intracellular 
radioactivity determined by liquid scintillation count­
ing. Pretreatment with D u P 753 was done by adding 
various concentrations of the antagonist (10~ 7 to 
10~ 4 mol /L) during the equilibration period. In one set 
of experiments, the cells were rinsed three times before 
the uptake was started. Protein was determined in all 
studies by the method of Lowry et a l . 2 2 
Determination of Cytosolic Calcium [Ca]{ Confluent 
monolayer cultures of rat aortic SMC were harvested by 
gently scraping the dish with a "rubber pol iceman." The 
cells were centrifuged for 5 min at 200 g and resus-
pended in DMEM. Fura-2 AM (Molecular Probes, 
Eugene, OR) was added at a final concentration of 
2.5 / /mol /L from a stock solution in dimethyl sulfoxide. 
The cells were then incubated for 30 min in the dark at 
room temperature. After loading, the cells were washed 
once with fresh culture med ium and resuspended in 
PSS at a concentration of 2 X 10 6 cel ls /mL. The Fura-2 
fluorescence was measured on a spectrofluorometer (LS 
5, Perkin Elmer, Oakbrook, IL). The cells were kept in 
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suspension by gentle stirring at 37°C. Stimulation of the 
cells was performed with various agents including an­
giotensin II, vasopressin, or DuP 753. Maximum fluores­
cence was obtained by addition of Triton X and mini­
m u m fluorescence by chelation of Ca with an excess of 
EDTA. The calculations of [Ca]j were performed accord­
ing to Grynkiewicz et al without corrections for extra­
cellular C a . 2 3 
Cytosolic calcium was also determined in h u m a n 
platelets using the fura-2 method described above. For 
comparison some measurements have been done with 
the Quin-2 method reported earlier. 2 4 
Statist ical Ana lys i s Data are presented as mean ± 
SEM. Statistical analysis was performed with a one-way 
analysis of variance. AP < .05 was considered signifi­
cant. 
RESULTS 
In terac t ion w i t h A n g II B ind ing The displacement of 
1 2 5 I - A n g II by cold angiotensin II or DuP 753 in h u m a n 
platelets is shown in the upper panel of Figure 1. Ang II 
competes with the binding of radiolabeled Ang II with a 
5 0 % binding inhibition (IC 5 0 ) at 7.5 X 1 0 " 9 m o l / L . The 
-11 -10 -9 -8 -7 -6 -5 
Log concentration 
Log concentration 
FIGURE 1. Effects of angiotensin II, DuP 753 or saralasin on 
125I-angiotensin binding to human platelets (upper panel, n = 6 in 
each curve) or rat aortic smooth muscle cells (lower panel, n = 3 in 
each curve). · angiotensin II, A DuP 753, • saralasin. 
binding of 1 2 5 I - A n g II is displaced by DuP 753 with an 
I C 5 0 of 5 to 6 X 10~ 8 mo l /L . In platelets, no displace­
ment of the labeled Ang II has been obtained with 
MMP, a nonrelevant peptide. Similar results have been 
found in rat aortic SMC as shown on the lower panel of 
Figure 1. In this cell type, the I C 5 0 for cold Ang II is at 
5 X 10~ 9 mo l /L . DuP 753 inhibits the Ang II binding 
with an I C 5 0 of 1 X 10~ 8 mo l /L , whereas saralasin com­
petes with Ang II with a higher affinity ( IC 5 0 of 5 to 
7 X 1 0 ~ 1 0 mol /L) . 
Ca lc ium Studies As shown in Figure 2, angiotensin II 
(10~ 8 mol /L) induces a significant increase in 4 5 C a 2 + 
efflux in rat aortic SMC w h e n compared to the un­
treated cells. This calcium efflux is completely blocked 
by pretreatment with DuP 753 ( 1 0 - 6 mol /L) . D u P 753 
has no effect, per se, on calcium efflux in these cells (data 
not shown) . 
A significant increase in 4 5 C a 2 + uptake is also ob­
served in aortic SMC after exposure to Ang II, an effect 
which can be prevented by preincubation of the cultures 
with DuP 753 (Figure 3). Interestingly, w h e n the cells 
are washed three times after incubation with D u P 753, 
higher doses of DuP 753 (10~ 4 m o l / L instead of 
1 0 " 6 mol /L) are needed to obtain an inhibition of the 
Ang II effect. In these conditions, at comparable molar­
ity ( 1 0 ~ 6 m o l / L ) , saralasin appears again to have a 
higher receptor affinity than DuP 753. 
In addition to the inhibition of the Ang II-induced 
increases in calcium fluxes, DuP 753 also dose-depen-
dently antagonizes the increase in cytosolic free calcium 
produced by Ang II (Figure 4). Indeed, cytosolic calcium 
increases from 144.3 ± 6.6 n m o l / L (n = 13) to 
367.4 ± 7.2 n m o l / L (n = 8, Ρ < .001) after stimulation 
with Ang II (10" 7 mol /L) . Pretreatment with D u P 753 
(10~ 4 mol /L) blunts the calcium response to Ang II with 
a [Ca]j at 169.9 ± 16 n m o l / L (P < .001 ν Ang II). With a 
lower dose of the antagonist (DuP 753 ,10~ 6 mol /L) , the 
Ang II stimulation is only partially a t tenuated resulting 
in a [Ca]i at 240 ± 6.5 n m o l / L (P < .01). Again, that 
D u P 753 has no effect, per se, even at a high concentra­
tion (10~ 4 mol /L) suggests that the compound has no 
agonistic effect. In these cells, DuP 753 does not affect 
the increase in cytosolic calcium induced by 10~ 7 m o l / L 
vasopressin (389 ± 35 n m o l / L , η = 4). 
In h u m a n platelets, no significant change in cytosolic 
calcium was observed after stimulation with angioten­
sin II w h e n [Ca]| was determined with the Fura-2 or the 
Quin-2 methods . 
D I S C U S S I O N 
Since stimulation of the angiotensin II receptor repre­
sents the ultimate step in the physiologic activation of 
the RAS, inhibition of angiotensin II binding by a spe­
cific receptor antagonist appears to be a logical and ef­
fective approach to decreasing the activity of this potent 
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FIGURE 2. Effects of DuP 753 on 
the changes in 45CaCl2 efflux in­
duced by angiotensin II in rat aortic 
smooth muscle cells. 
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vasoconstrictor system. DuP 753 is a new nonpeptide 
antagonist of angiotensin ΙΙ . 1 5 - 1 7 - 1 8 - 2 6 l n contrast to the 
peptidic analogs that have been used in the past to block 
the RAS, this compound has a long duration of action, 
can be administered orally and seems to be devoid of 
any agonistic e f f e c t . 1 5 1 7 " 1 9 , 2 6 
The ability of DuP 753 to compete with angiotensin II 
at the receptor has been demonstrated in animal tissues 
such as rat adrenal cortical microsomes and rat aortic 
smooth muscle cells. 1 7 In these two preparations, spe­
cific angiotensin II binding was inhibited by DuP 753 
with an I C 5 0 of about 2 X 1 0 ~ 8 nmol/L. In the present 
experiments, angiotensin II binding was performed 
both in primary cultures of rat aortic SMC and in human 
platelets to assess the ability to block receptors located in 
animal as well as in human cell types. In our smooth 
muscle cells, DuP 753 inhibited the Ang II binding with 
an I C 5 0 of 1 X 1 0 " 8 mol/L, a value which is comparable 
to those obtained in the above-mentioned tissues. 1 7 This 
new antagonist had less affinity for the angiotensin II 
receptor than saralasin, a finding which is also consist­
ent with previous observations. 1 7 The antagonist dis­
placed 100% of the specific binding which suggests the 
presence of only one receptor type in these SMC. 
Today, there is still little evidence available that DuP 
753 acts as a specific antagonist to angiotensin II in 
Continuous exposure to 
the antagonist 
Pre-treatment with the 
antagonist + washes 
FIGURE 3. Effects of DuP 753 or 
saralasin on the changes in 45CaCl2 
uptake induced by angiotensin II in 
rat aortic smooth muscle cells. The 
cells were either continuously ex­
posed to the antagonist orpretreated 
with the antagonist and washed be­
fore stimulation with angtiotensin 
11. 
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humans besides the recent observation that DuP 753 
administered orally to normotensive volunteers blunts 
the blood pressure response to exogenous angiotensin 
II . 1 9 The results of the present study demonstrate that 
this antagonist is indeed capable of competing with the 
binding of angiotensin II in human cells such as plate­
lets. The I C 5 0 for DuP 753 in platelets (5 Χ 1 0 " 8 mol/L) 
was again very similar to that reported in the literature 
for animal tissues. 1 7 
A physiologic action of angiotensin II on platelet func­
tion has still not been established although it has been 
suggested that angiotensin II might interfere with plate­
let aggregation.2 5 The second messenger system coupled 
to the platelet angiotensin II receptor is also unknown. 
Using the Fura-2 method, we could not demonstrate 
any significant change in cytosolic free calcium after 
stimulation of the platelets with angiotensin II whereas 
a marked increase in cytosolic calcium was found after 
stimulation with vasopressin.2 4 A relatively low number 
of angiotensin binding sites per platelet might explain 
the difficulty to obtain a measurable signal. 2 1 It is also 
possible that this receptor is not coupled to a calcium 
mediated pathway. 
Angiotensin II binding in human platelets was per­
formed originally in an attempt to monitor the degree of 
in vivo inhibition in volunteers receiving DuP 753 or­
ally. For this purpose, we measured angiotensin II bind­
ing on platelets harvested before and after administra­
tion of the drug (Ref. 19 and unpublished results). Even 
at peak blockade of the blood pressure response to exog­
enous angiotensin II no decrease in angiotensin II bind­
ing was observed on the platelets of these volunteers. 
Our observation that DuP 753 is easily removed from 
the receptor at concentrations of 10~ 6 mol/L when the 
cells are washed three times might explain why no bind­
ing inhibition was seen in platelets collected after admin­
istration of DuP 753. Most likely, the compound was 
displaced from the receptor during preparation of the 
platelets or during the repeated washes necessary to 
perform the angiotensin II binding. 
The results of the calcium studies indicate that DuP 
753 not only competes with the binding but also antago­
nizes effectively and specifically the cellular response to 
angiotensin II. Inhibition of angiotensin II-induced 4 5Ca 
efflux by DuP 753 has been shown previously in SMC 
and is confirmed by the present experiments. 1 7 In our 
hands, DuP 753 also blocked the cellular calcium uptake 
resulting from the angiotensin II stimulation. It is very 
unlikely that these effects of DuP 753 on calcium fluxes 
are due to a direct inhibitory effect of this compound on 
calcium channels. Indeed, previous studies have demon­
strated that DuP 753 has absolutely no affinity for cal­
cium channels. 1 7 
The measurement of free cytosolic calcium in vascular 
SMC is the definite way to look for an agonistic effect of 
the drug since cytosolic calcium is directly related to the 
activation of the receptor. In our aortic SMC, DuP 753 
had no effect per se on cytosolic calcium suggesting no 
activation of the receptor by the drug itself. Moreover, 
our results confirm the specificity of the compound as 
DuP 753 blocked the angiotensin II-induced increase in 
cytosolic calcium but not that produced by vasopressin. 
This observation is in agreement with previous reports 
demonstrating no inhibitory activity of DuP 753 on sev­
eral other receptors such as αλ, vasopressin, serotonin, 
histamine, acetylcholine, and bradykinin. 1 7 4 8 , 2 6 
Finally, one has to recall that DuP 753 is metabolized 
and that active metabolites with different receptor af­
finities might be generated. A metabolism of DuP 753 
has indeed been demonstrated in vivo in the rat and in 
vitro using human and rat liver microsomes. 2 7 All results 
obtained in vitro should therefore be interpreted 
cautiously particularly when trying to extrapolate from 
in vitro to in vivo antagonistic actions of the compound. 
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Taken together, the results of the present experiments 
confirm that DuP 753 is an effective antagonist of an­
giotensin II which inhibits Ang II binding to its receptor 
in both animal and human cells and selectively blocks 
the cellular response to angiotensin II. 
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